Aclarion, Inc. said it has signed a commercial agreement with Weill Cornell Medicine. The deal brings Nociscan to Weill Cornell Medicine and Och Spine at NewYork-Presbyterian/Weill Cornell Medical Center and to a multidisciplinary spine team led by physician and principal investigator Jaspal Ricky Singh, MD.
The agreement is also tied to a study titled A Prospective Review of Bone Marrow Aspirate Stem Cell Concentrate (BMAC) for Osteoarthritis and Degenerative Disc Disease, conducted under IRB Protocol No. 22-06024915. The initial study will examine whether the dose and quantity of bone marrow aspirate stem cell concentrate used for spine-related osteoarthritis and/or degenerative disc disease affect patient-reported outcomes for function and pain.
A subset of spine patients selected based on Dr. Singh’s clinical evaluation will also be eligible for Nociscan.
“Our team takes a comprehensive approach to the treatment of spinal disorders. Our multidisciplinary approach to treat pain includes physical therapy and various interventional techniques,” said Jaspal Ricky Singh, MD, Vice Chair and Director of Interventional Spine at Weill Cornell Medicine and Rehabilitation Medicine Specialist at Och Spine at NewYork-Presbyterian/Weill Cornell Medical Center. “Our pioneering research into discogenic low back pain and cBMA (concentrated bone marrow aspirate) is an ideal opportunity to utilize the insights provided by Nociscan.”
This is newsworthy because it expands Nociscan’s use through a commercial agreement with a major academic medical center and connects the technology to an ongoing clinical study focused on spine pain and patient-reported outcomes.
Source: Press Release
